Inmune Bio (INMB) Total Liabilities (2017 - 2026)
Inmune Bio (INMB) posted Total Liabilities of $6.2 million for Q1 2026, down 29.83% sequentially from $8.8 million in Q4 2025, and down 23.79% YoY from $8.1 million in Q1 2025.
Inmune Bio (INMB) Total Liabilities (2017 - 2026) Analysis & Trends
Inmune Bio has reported Total Liabilities for 10 years, with the latest figure at $6.2 million in Q1 2026.
- Quarterly Total Liabilities fell 23.79% year-over-year to $6.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.2 million (down 23.79% YoY) and the FY2025 annual result came in at $8.8 million, up 18.25% from the prior year.
- Total Liabilities retreated to $6.2 million in Q1 2026 per INMB's latest filing, from $8.8 million in the prior quarter.
- Over five years, Total Liabilities peaked at $21.7 million in Q4 2022 and troughed at $6.2 million in Q1 2026.
- A 5-year average of $14.6 million and a median of $17.8 million in 2024 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2022 and 2024: Total Liabilities surged 709.3% in 2022, then plunged 60.42% in 2024.
- Over 5 years, Total Liabilities stood at $21.7 million in 2022, then declined by 13.04% to $18.9 million in 2023, then slumped by 60.42% to $7.5 million in 2024, then climbed by 18.25% to $8.8 million in 2025, then slipped by 29.83% to $6.2 million in 2026.
- According to Business Quant data, Total Liabilities over the past three periods registered $6.2 million, $8.8 million, and $8.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.64 Bn | 130.78 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 85.89 Bn | 77.90 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 65.11 Bn | 59.93 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 55.83 Bn | 50.69 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 42.01 Bn | 36.91 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.63 Bn | 28.32 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 27.65 Bn | 9.26 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.30 Bn | 26.47 Bn | - | 10.03 Bn |
| 10 | Inmune Bio | 60.78 Mn | 42.37 Mn | - | 6.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.48 Mn |
| Mar 31, 2026 | 6.19 Mn |
| Dec 31, 2025 | 8.83 Mn |
| Sep 30, 2025 | 7.98 Mn |
| Jun 30, 2025 | 8.82 Mn |
| Mar 31, 2025 | 8.13 Mn |
| Dec 31, 2024 | 7.47 Mn |
| Sep 30, 2024 | 14.11 Mn |
| Jun 30, 2024 | 15.37 Mn |
| Mar 31, 2024 | 17.81 Mn |
| Dec 31, 2023 | 18.86 Mn |
| Sep 30, 2023 | 17.97 Mn |
| Jun 30, 2023 | 19.07 Mn |
| Mar 31, 2023 | 18.68 Mn |
| Dec 31, 2022 | 21.69 Mn |
| Sep 30, 2022 | 20.09 Mn |
| Jun 30, 2022 | 17.88 Mn |
| Mar 31, 2022 | 18.71 Mn |
| Dec 31, 2021 | 19.72 Mn |
| Sep 30, 2021 | 19.42 Mn |